31.07.2023 - Replimune Group, Inc. (NASDAQ:REPL), a clinical stage biotechnology company pioneering the development of a novel portfolio of tumor-directed oncolytic immunotherapies, and Incyte (NASDAQ:INCY), a global biopharmaceutical company, today announced a . Seite 1
Incyte (INCY) and Replimune (REPL) Enter into Clinical Trial Collaboration and Supply Agreement to Evaluate RP1 and INCB99280 streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Replimune Group, Inc. (NASDAQ:REPL – Get Rating)’s share price gapped up before the market opened on Thursday . The stock had previously closed at $23.48, but opened at $24.60. Replimune Group shares last traded at $24.39, with a volume of 44,521 shares. Wall Street Analysts Forecast Growth A number of research analysts have weighed in […]
Replimune Group (NASDAQ:REPL – Get Rating) had its target price upped by HC Wainwright from $50.00 to $51.00 in a research report sent to investors on Monday morning, The Fly reports. HC Wainwright also issued estimates for Replimune Group’s Q1 2024 earnings at ($0.80) EPS, Q2 2024 earnings at ($0.84) EPS, Q3 2024 earnings at […]
Replimune Group (NASDAQ:REPL – Get Rating) had its price target raised by HC Wainwright from $50.00 to $51.00 in a research report released on Monday, The Fly reports. HC Wainwright also issued estimates for Replimune Group’s Q1 2024 earnings at ($0.80) EPS, Q2 2024 earnings at ($0.84) EPS, Q3 2024 earnings at ($0.88) EPS, Q4 […]